CD274 and triple-negative breast carcinoma: As a target with broad spectrum applicability, PD-L1 is highly expressed in a variety of solid tumors (such as lung cancer, melanoma, triple-negative breast cancer) and hematological tumors (such as Hodgkin’s lymphoma) [34].